Jacobio Pharmaceuticals Patent on Solid Forms of Compound I or Salts Thereof

USPTO published Jacobio Pharmaceuticals' patent application for solid forms of Compound I, a heterocyclic compound designated as (S)-5-((1-(3-(5-methyl-3-(trifluoromethyl)-8,9-dihydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazin-7(6H)-yl)-3-oxopropoxy)propan-2-yl)oxy)-4-(trifluoromethyl)pyridazin-3(2H)-one, along with its salts. The patent covers preparation methods and pharmaceutical compositions containing the compound.\n\nPharmaceutical and biotech companies developing cancer therapeutics should review this patent for potential freedom-to-operate concerns and assess whether licensing or design-around strategies may be needed. Researchers and investors may find licensing or collaboration opportunities with Jacobio Pharmaceuticals.